BOSTON and VANCOUVER, BC, Nov. 10, 2025 /PRNewswire/ -- Alpha-9 Oncology ("Alpha-9" or "the Company"), a clinical-stage radiopharmaceutical company developing targeted cancer therapies, today ...
Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company's imaging agent, A9-3202, which entered the clinic last year Robert Meehan, M.D., ...
BOSTON and VANCOUVER, BC, Oct. 15, 2024 /PRNewswire/ -- Alpha-9 Oncology ("Alpha-9" or the "Company"), a clinical stage company developing radiopharmaceuticals for the treatment of cancer patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results